Change - Announcement of Cessation::Cessation of Interim Chief Financial Officer
Issuer & Securities
THOMSON MEDICAL GROUP LIMITED
THOMSON MEDICAL GROUP LIMITED - SG1M49904634 - A50
Change - Announcement of Cessation
Date &Time of Broadcast
Announcement Sub Title
Cessation of Interim Chief Financial Officer
Submitted By (Co./ Ind. Name)
Lim Hoi Leong
Description (Please provide a detailed description of the event in the box below)
Mr. Tan Zing Yuen has relinquished his role as the interim Chief Financial Officer with effect from 15 March 2019 and will assume the role of Chief Risk Officer and Director, Group Finance.
Name Of Person
Tan Zing Yuen
Is effective date of cessation known?
If yes, please provide the date
Detailed Reason (s) for cessation
Mr Wilson Sam has been appointed as Group Chief Financial Officer of the Company in place of Mr Tan Zing Yuen.
Are there any unresolved differences in opinion on material matters between the person and the board of directors, including matters which would have a material impact on the group or its financial reporting?
Is there any matter in relation to the cessation that needs to be brought to the attention of the shareholders of the listed issuer?
Any other relevant information to be provided to shareholders of the listed issuer?
Date of Appointment to current position
Does the AC have a minimum of 3 members (taking into account this cessation)?
Number of Independent Directors currently resident in Singapore (taking into account this cessation)
Number of cessations of appointments specified in Listing Rule 704 (7) or Catalist Rule 704 (6) over the past 12 months
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)
Chief Risk Officer and Director, Group Finance
Role and responsibilities
As Chief Risk Officer, Mr Tan will report to the Group Chief Executive Officer and his responsibilities will cover the risk management and internal controls of the Group. Mr Tan will report to the Group Chief Financial Officer in his role as Director, Group Finance covering the corporate finance, investor relations, corporate and regulatory compliance and financial and management reporting functions.
Familial relationship with any director and/ or substantial shareholder of the listed issuer or of any of its principal subsidiaries
Shareholding interest in the listed issuer and its subsidiaries?
50,000 shares 100,000 warrants in the Issuer
Past (for the last 5 years)
Total size =41K